160 related articles for article (PubMed ID: 11427987)
1. Novel clinical strategies for the treatment of pancreatic carcinoma.
Günzburg WH; Salmons B
Trends Mol Med; 2001 Jan; 7(1):30-7. PubMed ID: 11427987
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs in pancreatic cancer.
Ducreux M; Boige V; Malka D
Expert Opin Emerg Drugs; 2004 May; 9(1):73-89. PubMed ID: 15155137
[TBL] [Abstract][Full Text] [Related]
3. Novel treatments and therapies in development for pancreatic cancer.
Günzburg WH; Löhr M; Salmons B
Expert Opin Investig Drugs; 2002 Jun; 11(6):769-86. PubMed ID: 12036421
[TBL] [Abstract][Full Text] [Related]
4. Developments in the systemic therapy of pancreatic cancer.
el-Rayes BF; Shields AF; Vaitkevicius V; Philip PA
Cancer Invest; 2003; 21(1):73-86. PubMed ID: 12643012
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Expert Rev Anticancer Ther; 2002 Aug; 2(4):426-36. PubMed ID: 12647986
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: a review of recent advances.
Eckel F; Schneider G; Schmid RM
Expert Opin Investig Drugs; 2006 Nov; 15(11):1395-410. PubMed ID: 17040199
[TBL] [Abstract][Full Text] [Related]
8. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Weitman S; Marty J; Jolivet J; Locas C; Von Hoff DD
Clin Cancer Res; 2000 Apr; 6(4):1574-8. PubMed ID: 10778991
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
[TBL] [Abstract][Full Text] [Related]
10. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study.
Löhr M; Bago ZT; Bergmeister H; Ceijna M; Freund M; Gelbmann W; Günzburg WH; Jesnowski R; Hain J; Hauenstein K; Henninger W; Hoffmeyer A; Karle P; Kröger JC; Kundt G; Liebe S; Losert U; Müller P; Probst A; Püschel K; Renner M; Renz R; Saller R; Salmons B; Walter I
J Mol Med (Berl); 1999 Apr; 77(4):393-8. PubMed ID: 10353444
[No Abstract] [Full Text] [Related]
11. [Molecular-based treatment concepts in advanced pancreatic cancer].
Boeck S; Moosmann N; Stemmler HJ; Heinemann V
Dtsch Med Wochenschr; 2007 Apr; 132(15):818-22. PubMed ID: 17427093
[No Abstract] [Full Text] [Related]
12. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
13. What's new in pancreatic cancer treatment pipeline?
Von Hoff DD
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):315-26. PubMed ID: 16549330
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
[TBL] [Abstract][Full Text] [Related]
15. Present and future treatment of pancreatic cancer.
Heinemann V
Semin Oncol; 2002 Jun; 29(3 Suppl 9):23-31. PubMed ID: 12094335
[TBL] [Abstract][Full Text] [Related]
16. [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Gligorov J; André T; Epaud C; Culine S
Bull Cancer; 2002 Aug; 89 Spec No():S134-44. PubMed ID: 12449045
[TBL] [Abstract][Full Text] [Related]
17. Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
Mercadé E; Cascalló M; Carrió M; Calbó J; Gómez-Treviño A; Fillat C; Gómez-Foix AM; Mazo A
Ann Oncol; 2001 Mar; 12(3):379-88. PubMed ID: 11332152
[TBL] [Abstract][Full Text] [Related]
18. Biological approaches to therapy of pancreatic cancer.
Wong HH; Lemoine NR
Pancreatology; 2008; 8(4-5):431-61. PubMed ID: 18724071
[TBL] [Abstract][Full Text] [Related]
19. New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Saif MW
JOP; 2008 Jul; 9(4):391-7. PubMed ID: 18648128
[TBL] [Abstract][Full Text] [Related]
20. [Gene therapy of pancreatic cancer with microencapsulated CYP2B1-expressing cells].
Löhr M; Faulmann G; Hummel F; Singer MV
Onkologie; 2001 Sep; 24 Suppl 5():60-4. PubMed ID: 11600815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
